The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Boccardo F;Viale G;Wang Y;Rubino C;Bruzzi P;Del Mastro L;Sertoli Mr;Rubagotti A;
2017-01-01
Abstract
The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
emss-75008.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
1.12 MB
Formato
Adobe PDF
|
1.12 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
